Treatment of Ménétrier's Disease With EGF Receptor Blockade
- Evaluate clinical and biochemical parameter response in patients with Ménétrier disease
at high risk of developing gastric cancer treated with cetuximab.
OUTLINE: This is a non-randomized study.
Patients receive cetuximab IV on days 1, 8, 15, and 22. Treatment repeats every 4 weeks in
the absence of disease progression or unacceptable toxicity.
Patients complete a quality of life questionnaire at baseline and during week 4.
PROJECTED ACCRUAL: A total of 10 patients will be accrued for this study.
Allocation: Non-Randomized, Primary Purpose: Treatment
Robert J. Coffey, MD
Vanderbilt-Ingram Cancer Center
United States: Federal Government
|Vanderbilt-Ingram Cancer Center||Nashville, Tennessee 37232-6838|
|Vanderbilt-Ingram Cancer Center - Cool Springs||Nashville, Tennessee 37064|
|Vanderbilt-Ingram Cancer Center at Franklin||Nashville, Tennessee 37064|